UBS reviews upcoming events, conference calls, and conference schedules for the US pharmaceuticals and biotechnology sectors

Overview

UBS Global Research published an “All-Access Pass” resource for the US pharmaceuticals and biotechnology industries, primarily summarizing corporate access events, analyst marketing activities, expert conference calls, and industry conference schedules over the coming months. The report covers relevant healthcare events in the US, Europe, and Asia, and includes valuation methodologies, industry risks, and UBS research disclaimers.

Core views

The core message is not to provide directional buy or sell recommendations, but to alert investors to upcoming corporate communications and thematic catalysts in the pharmaceuticals and biotechnology sectors. July highlights include the TRAX virtual NDR, OLMA European NDR, IDYA virtual NDR, an EU Pharma third-quarter catalysts call, a GMAB head and neck cancer expert call, and a US Healthcare introductory call. The second half of the year also includes healthcare conferences and corporate days in Japan, Switzerland, London, Hong Kong, and Palm Beach.

Analysis framework

The report uses an event-mapping approach, presenting information by corporate access events, recent and upcoming conference calls, analyst roadshows, and conferences. Its methodology disclosure states that pharmaceutical and biotechnology companies are generally valued using P/E or EV/sales multiples, supplemented by a DCF framework.

Methodology notes

• Valuation methodsP/E, EV/sales, and DCF

  Pharmaceutical and biotechnology valuation framework

  The report discloses that sector valuations generally use price-to-earnings or enterprise-value-to-sales multiples, supplemented by a DCF framework.

• Event researchCorporate access and conference calendar

  Industry catalyst tracking

  NDRs, expert conference calls, analyst roadshows, and industry conference schedules help investors track potential catalysts and management communication windows.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• US pharmaceutical and biotechnology stocks

  Core assets covered by the report

  Strengths

  Provides corporate access, conference call, and conference schedules, helping track clinical, regulatory, and commercialization catalysts.

  Weaknesses

  Does not provide specific company ratings, financial forecasts, or price targets, making it difficult to directly derive single-stock valuation conclusions.

  Comparison

  Compared with a formal company deep-dive report, this material is more focused on the event calendar and marketing schedule.

  Risks

  Disappointing drug launches, clinical failures, regulatory setbacks, changes in healthcare reimbursement and pricing policies, and post-patent competition.

• Small- and mid-cap biotechnology stocks

  Assets emphasized in the risk disclosures

  Strengths

  Binary events may create high-risk, high-return opportunities.

  Weaknesses

  High volatility, with price movements easily influenced by clinical expectations, options trading, and market speculation.

  Comparison

  Compared with large-cap biopharmaceutical companies, small- and mid-cap biotechnology companies are more sensitive to individual clinical or regulatory events.

  Risks

  Clinical trial failures, complex data interpretation, financing and liquidity pressures, and sharp share-price volatility.

Key data

• July corporate access eventsTRAX, OLMA, IDYAIncludes the First Tracks Biotherapeutics virtual NDR, Olema European NDR, and Ideaya Biosciences virtual NDR.
• Recent conference call topicsEU Pharma 3Q catalysts、US Healthcare 101、GMAB head and neck cancer、GLP-1、milvexian、Lp(a)Includes both upcoming conference calls and replay content.
• Key conferencesUBS Kansai Summit、Best of Switzerland Conference、Global Healthcare Conference、UBS Global Biopharma London Conference、UBS Asia Healthcare Corporate DayThe schedule spans August to December 2026, with locations including Osaka, Palm Beach, London, and Hong Kong.
• Recommended finalization time2026-07-03 03:05 PM GMTFrom the report disclosure section.
• Valuation methodsP/E or EV/sales multiples, supplemented by DCFUsed in valuation disclosures for covered pharmaceutical and biotechnology companies.

Impact & implications

The report's primary value for investment decisions lies in providing event and communication windows rather than forming new fundamental views on individual companies. Investors can organize monitoring around clinical data, regulatory developments, drug launch performance, and policy changes, with particular attention to the volatility risks of small- and mid-cap biotechnology stocks driven by binary events.

Risks

• Drug launch or commercialization performance may fall short of expectations.
• Clinical trials may fail, be terminated, or produce key data below expectations.
• Decisions by regulatory agencies such as the FDA and EMEA may have negative effects.
• Policy risks related to the US healthcare system, drug pricing, tariffs, and changes to FDA organization.
• Competition from biosimilars after patent protection expires.
• The small- and mid-cap biotechnology sector is highly volatile; binary events and market speculation may cause sharp share-price fluctuations.

What to watch

• First Tracks Biotherapeutics (TRAX) virtual NDRs on July 9 and 15.
• Olema (OLMA) European NDR from July 13 to 16.
• Ideaya Biosciences (IDYA) virtual NDR from July 21 to 22.
• EU Pharma third-quarter catalysts call, GMAB head and neck cancer expert call, and US Healthcare 101 call.
• UBS healthcare-related summits, corporate days, and biopharmaceutical conferences from August to December.
• Follow-up data and market impact related to GLP-1, milvexian, Lp(a), and other themes.